Chemistry:Aclarubicin
From HandWiki
Aclarubicin (INN) or aclacinomycin A[1] is an anthracycline drug[2] that is used in the treatment of cancer in China. It was previously approved for use in Europe but was discontinued in 2004 due to being rarely prescribed and unprofitable.
However, it has subsequently been reevaluated[3] due to possible advantages over other chemotherapeutic drugs in the treatment of certain cancers such as acute myeloid leukemia.[4][5]
Soil bacteria Streptomyces galilaeus can produce aclarubicin.
It can induce histone eviction from chromatin upon intercalation.[6][7]
References
- ↑ CID 451415 from PubChem
- ↑ "Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II". Cancer Research 51 (19): 5093–5099. October 1991. PMID 1655244.
- ↑ "One man's mission to revive a forgotten, life-saving cancer drug". The Guardian. 27 July 2024. https://www.theguardian.com/science/article/2024/jul/27/one-mans-mission-to-revive-a-forgotten-life-saving-cancer-drug.
- ↑ "A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome". Journal of Hematology & Oncology 4. November 2011. doi:10.1186/1756-8722-4-46. PMID 22082134.
- ↑ "Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing". Cancer Chemotherapy and Pharmacology 94 (2): 123–139. July 2024. doi:10.1007/s00280-024-04693-1. PMID 38965080.
- ↑ "Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin". Nature Communications 4. 2013. doi:10.1038/ncomms2921. PMID 23715267. Bibcode: 2013NatCo...4.1908P.
- ↑ "Chemical profiling of the genome with anti-cancer drugs defines target specificities". Nature Chemical Biology 11 (7): 472–480. July 2015. doi:10.1038/nchembio.1811. PMID 25961671.
 |  |
